Search | Clinical Trials Finder

Conditions: Alzheimer's Disease
Interventions: CAD106, Placebo, Alum, MF59; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Up to 85 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more

Conditions: Aging Frailty
Interventions: Longeveron Mesenchymal Stem Cells (LMSCs), Fluzone High Dose Vaccine; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 6
States / cities: Coral Gables, Florida • Fort Myers, Florida • Miami, Florida + 2 more

Conditions: Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study); Genetic · Procedure
Lead sponsor: Celladon Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 22
States / cities: San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more

Conditions: Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions: PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obese But Otherwise Healthy Participants
Interventions: CRB-913, Placebo; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Chandler, Arizona • Rancho Cucamonga, California + 12 more

Conditions: PTSD, Posttraumatic Stress Disorder
Interventions: Ketamine, Placebo/Saline; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: West Haven, Connecticut • Minneapolis, Minnesota • San Antonio, Texas

Conditions: Autism Disorder
Interventions: STX209 (15mg), placebo, STX209 (30mg); Drug
Lead sponsor: Timothy Roberts; Other
Eligibility: 14 Years to 17 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dry Eye Disease, Dry Eye Syndrome
Interventions: AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more

Conditions: Acute Pain, Postoperative
Interventions: LTG-001 High Dose, LTG-001 Mid Dose, LTG-001 Low Dose, Placebo, Suzetrigine; Drug · Other
Lead sponsor: Latigo Biotherapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions: RO7204239, RO7204239 Matching Placebo, Tirzepatide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more

Conditions: Ulcerative Colitis
Interventions: GB004, Placebo; Drug
Lead sponsor: GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Monroe, Louisiana

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more

Conditions: Malaria
Interventions: Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions: Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration; Drug · Radiation · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 200
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more

Conditions: Schizophrenia, Impaired Cognition
Interventions: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 38
States / cities: Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more

Conditions: Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions: SPR720, Placebo, Open-label Standard of Care; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more

Conditions: Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions: Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Epilepsy
Interventions: Vinpocetine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Precancerous Condition
Interventions: perillyl alcohol, placebo; Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Alcoholism
Interventions: Ethanol High Dose, Ethanol Low Dose, and Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 30 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Post-operative Pain
Interventions: Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®, Panadeine® Extra, Placebo; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 16 Years and older
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza
Interventions: NasoVAX; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Papulopustular Rosacea
Interventions: omiganan, placebo; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Santa Monica, California • New Haven, Connecticut + 14 more

Search by objective public record fields.

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Study in Healthy Adults Evaluating PF-07202954

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

CAP-Ketamine for Antidepressant Resistant PTSD

MEG Study of Acute STX209 Effects in ASD

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

GB004 in Adult Subjects With Active Ulcerative Colitis

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy

Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses

Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism

Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

A Twelve Week Safety and Efficacy Study in Rosacea